Vertex Pharma (VRTX) Posts Smaller Q4 Loss
Get Alerts VRTX Hot Sheet
Revenue Growth %: +8.4%
Financial Fact:
Sales, general and administrative expenses: 106.06M
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of ($0.55), $0.10 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $145 million versus the consensus estimate of $137.5 million.
"The potential approval and launch of the combination of lumacaftor and ivacaftor and continued label and geographic expansion for KALYDECO are expected to significantly increase both the number of people treated with our medicines and our revenues to support the long-term growth of our business," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "As our revenues grow over the coming years, we remain committed to both controlling our operating expenses to generate significant earnings growth and to investing in research and development to create transformative new medicines."
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- NaaS Technology Inc. (NAAS) Reports Q1 Loss of $0.29
- Forian Inc. (FORA) Tops Q4 EPS by 3c, provides outlook
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!